GlassScriptPhysician profile
Martin M Goldstein
NPI 1831162189
$4,158.24
in general payments reported to CMS, 2019-2025
29 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $1,739 · 2021: $829 · 2022: $256 · 2023: $167 · 2024: $150 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.61 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $1,717.91 | 2020-2022 | |
| Astellas Pharma US INC | $671.67 | 2019-2022 | |
| Allergan, INC. | $176.16 | 2019 | |
| Laborie Medical Technologies Corp. | $152.07 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Boston Scientific Corporation | $119.58 | 2019-2022 | |
| Ethicon US, LLC | $116.67 | 2025 | Vistaseal, Stratafix |
| Koelis INC. | $98.85 | 2021 | |
| Blue Earth Diagnostics | $97.58 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $87.98 | 2019-2022 | |
| Pfizer INC. | $83.08 | 2019-2020 | |
| Myovant Sciences INC. | $78.43 | 2021-2022 | |
| Janssen Biotech, INC. | $77.36 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $67.49 | 2020-2023 | |
| Calyxo, INC. | $62.33 | 2023-2024 | Cvac Aspiration System |
| Dendreon Pharmaceuticals LLC | $56.68 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $54.97 | 2022-2025 | Itind System |
| Davol INC. | $51.38 | 2024 | Channel Drain |
| Tolmar, INC. | $49.34 | 2024-2025 | Jatenzo, Eligard |
| Urovant Sciences INC | $43.94 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $43.84 | 2024-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $43.38 | 2024-2025 | Gemtesa |
| Metuchen Pharmaceuticals | $37.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Janssen Scientific Affairs, LLC | $31.07 | 2025 | Erleada |
| Varian Medical Systems, INC. | $29.92 | 2019 | |
| Endo Pharmaceuticals INC. | $28.76 | 2020-2021 | |
| Coloplast Corp | $17.72 | 2025 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.05 | 2019 | |
| Verity Pharmaceuticals INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.